PWPeng Wang

Peng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peng Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Na Zhu

    Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

    1 shared publication
  • Xin Li

    Department of Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China

    1 shared publication
  • Xin Wang

    Department of Center of Integrated Traditional Chinese and Western Medicine, Peking University Ditan Teaching Hospital, No. 8, Jingshun East Street, Chaoyang District, Beijing 100015, China

    1 shared publication
  • Xinyu Cui

    Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

    1 shared publication
  • Yanyan Li

    Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

    1 shared publication
  • Yingying Lin

    Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing 100015, China

    1 shared publication

Latest Publications

  • Open Access

    Association Between Retinol-Binding Protein 4 Levels and Hepatitis C Virus Infection: A Meta-Analysis

    by Yingying Lin, Xinyu Cui, Na Zhu, Yanyan Li, Peng Wang, Xin Wang, Yunyun Yi, Xin Li

    Background and Objectives: The relationship between circulating retinol-binding protein 4 (RBP4) levels and hepatitis C virus (HCV) infection remains unclear. This study aims to systematically assess RBP4 expression in patients with HCV and its correlation with disease severity. Materials and Methods: We searched the Embase, PubMed, and Cochrane databases for relevant studies up to 1 January 2024. This study was registered on PROSPERO (CRD42023489051). Results: Our analysis included eight studies with 2612 participants (1152 controls and 1282 patients with HCV). Overall, RBP4 levels did not significantly differ between patients with HCV and controls (SMD: −0.36; 95% CI: −0.94, 0.23; p = 0.23). However, in a subgroup of Asian subjects, patients with HCV showed significantly lower RBP4 levels (SMD: −0.40; 95% CI: −0.49, −0.31; p = 0.10). Additionally, a negative correlation between RBP4 levels and disease severity was observed across all studied populations. Conclusions: RBP4 levels may vary due to HCV genotype, ethnicity, and environmental factors. In the context of HCV infection, RBP4 levels appear to reflect the severity of disease progression. Our findings indicate that RBP4 could serve as a biomarker for HCV disease progression. Further research is needed to elucidate the complex mechanisms of RBP4 in HCV infection.